Gillian M Duchesne

List of Publications by Year
in descending order

102 papers	4,145 citations	126907 33 h-index	114465 63 g-index
106 all docs	106 docs citations	106 times ranked	3842 citing authors

#	Article	IF	Citations
1	Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncology, The, 2005, 6, 841-850.	10.7	351
2	The dose-rate effect in human tumour cells. Radiotherapy and Oncology, 1987, 9, 299-310.	0.6	257
3	Psychosocial adjustment of female partners of men with prostate cancer: a review of the literature. Psycho-Oncology, 2006, 15, 937-953.	2.3	197
4	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2020, 21, 1331-1340.	10.7	197
5	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06) Tj ETQq1 1 0.784314 rgBT /O The, 2016, 17, 727-737.	10.7	172
6	Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the Î±/Î² Ratio of Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 24-33.	0.8	153
7	Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiotherapy and Oncology, 2009, 91, 232-236.	0.6	139
8	A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. International Journal of Radiation Oncology Biology Physics, 2000, 47, 379-388.	0.8	127
9	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncology, The, 2014, 15, 1076-1089.	10.7	121
10	The psychosocial impact of prostate cancer on patients and their partners. Medical Journal of Australia, 2006, 185, 428-432.	1.7	115
11	Online Adaptive Radiotherapy for Muscle-Invasive Bladder Cancer: Results of a Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 765-771.	0.8	108
12	High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1889-1896.	0.8	107
13	Direct 2-Arm Comparison Shows Benefit of High-Dose-Rate Brachytherapy Boost vs External Beam Radiation Therapy Alone for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 679-685.	0.8	90
14	Measurement of lung tumor volumes using three-dimensional computer planning software. International Journal of Radiation Oncology Biology Physics, 2002, 53, 566-573.	0.8	88
15	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncology, The, 2019, 20, 267-281.	10.7	84
16	Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiation Oncology, 2011, 6, 145.	2.7	73
17	High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy, 2010, 9, 27-35.	0.5	72
18	Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiotherapy and Oncology, 2006, 81, 9-17.	0.6	70

#	Article	IF	Citations
19	Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiotherapy and Oncology, 2009, 90, 400-407.	0.6	70
20	Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiotherapy and Oncology, 2007, 84, 128-134.	0.6	60
21	Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. Radiotherapy and Oncology, 2004, 73, 33-38.	0.6	52
22	Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiotherapy and Oncology, 2013, 107, 140-146.	0.6	52
23	Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2015, 115, 301-307.	0.6	52
24	Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, The, 2012, 13, 1260-1270.	10.7	49
25	Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 693-702.	0.8	48
26	Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiotherapy and Oncology, 2005, 77, 117-125.	0.6	47
27	Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncology, The, 2017, 18, 1192-1201.	10.7	45
28	Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 2012, 105, 184-192.	0.6	39
29	Development and evaluation of a training program for therapeutic radiographers as a basis for online adaptive radiation therapy for bladder carcinoma. Radiography, 2010, 16, 14-20.	2.1	38
30	Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the <scp>TROG</scp> 03.04 â€˜<scp>RADAR</scp>â€™ trial. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 247-257.	1.8	36
31	An in vivo investigative protocol for HDR prostate brachytherapy using urethral and rectal thermoluminescence dosimetry. Radiotherapy and Oncology, 2009, 91, 243-248.	0.6	35
32	Assuring high quality treatment delivery in clinical trials â€“ Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 â€œRADARâ€•set-up accuracy study. Radiotherapy and Oncology, 2009, 90, 299-306.	0.6	35
33	Seminal vesicle interfraction displacement and margins in image guided radiotherapy for prostate cancer. Radiation Oncology, 2012, 7, 139.	2.7	35
34	A Comparison of the Prognostic Value of Early PSA Test-Based Variables Following External Beam Radiotherapy, With or Without Preceding Androgen Deprivation: Analysis of Data From the TROG 96.01 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2011, 79, 385-391.	0.8	34
35	Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiotherapy and Oncology, 2003, 68, 255-267.	0.6	33
36	Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2016, 121, 98-102.	0.6	33

#	Article	IF	Citations
37	A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer, 2009, 9, 419.	2.6	32
38	An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. International Journal of Radiation Oncology Biology Physics, 2006, 65, 351-357.	0.8	31
39	Cognitive existential couple therapy (<scp>CECT</scp>) in men and partners facing localised prostate cancer: a randomised controlled trial. BJU International, 2015, 115, 35-45.	2.5	31
40	Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1082-1087.	0.8	30
41	Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. Brachytherapy, 2013, 12, 628-636.	0.5	30
42	Interfraction Prostate Rotation Determined from In-Room Computerized Tomography Images. Medical Dosimetry, 2011, 36, 188-194.	0.9	29
43	A randomised, doubleâ€blind, placeboâ€controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 81-88.	1.8	28
44	What to do for prostate cancer patients with a rising PSA?â€"a survey of Australian practice. International Journal of Radiation Oncology Biology Physics, 2003, 55, 986-991.	0.8	27
45	Identification of intermediate-risk prostate cancer patients treated with radical radiotherapy suitable for neoadjuvant hormone studies. Radiotherapy and Oncology, 1996, 38, 7-12.	0.6	26
46	Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Transâ€Tasman Radiation Oncology Group (<scp>TROG</scp>) 03.04 Randomised Androgen Deprivation and Radiotherapy (<scp>RADAR</scp>) randomized controlled trial for locally advanced prostate cancer. BJU International, 2014, 114, 344-353.	2.5	26
47	Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trial. BMC Cancer, 2016, 16, 637.	2.6	26
48	Assessment of i-125 prostate implants by tumor bioeffect. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1405-1413.	0.8	25
49	Coping Patterns and Psychosocial Distress in Female Partners of Prostate Cancer Patients. Psychosomatics, 2009, 50, 375-382.	2.5	25
50	Percentage of Biopsy Cores Positive for Malignancy and Biochemical Failure Following Prostate Cancer Radiotherapy in 3,264 Men: Statistical Significance Without Predictive Performance. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1169-1175.	0.8	24
51	Carcinoid tumour of the orbital muscles: A rare occurrence. Journal of Medical Imaging and Radiation Oncology, 2001, 45, 179-181.	0.6	23
52	Comparison of CT on Rails With Electronic Portal Imaging for Positioning of Prostate Cancer Patients With Implanted Fiducial Markers. International Journal of Radiation Oncology Biology Physics, 2009, 74, 906-912.	0.8	21
53	Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology, 2003, 61, 179-183.	1.0	20
54	Cognitive Existential Couple Therapy for newly diagnosed prostate cancer patients and their partners: a descriptive pilot study. Psycho-Oncology, 2013, 22, 465-469.	2.3	20

#	Article	IF	Citations
55	Management of localised prostate cancer: state of the art. Medical Journal of Australia, 1998, 169, 11-12.	1.7	19
56	A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiotherapy and Oncology, 2014, 112, 187-193.	0.6	19
57	What defines intermediate-risk prostate cancer? Variability in published prognostic models. International Journal of Radiation Oncology Biology Physics, 2004, 58, 11-18.	0.8	18
58	Prostate implant evaluation using tumour control probabilityâ€"the effect of input parameters. Physics in Medicine and Biology, 2004, 49, 3649-3664.	3.0	18
59	Fundamental bases of combined therapy in lung cancer: cell resistance to chemotherapy and radiotherapy. Lung Cancer, 1994, 10, S67-S72.	2.0	17
60	Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. Journal of Medical Imaging and Radiation Oncology, 2002, 46, 384-389.	0.6	17
61	PSA response signatures â€“ a powerful new prognostic indicator after radiation for prostate cancer?. Radiotherapy and Oncology, 2009, 90, 382-388.	0.6	17
62	The Detectability and Localization Accuracy of Implanted Fiducial Markers Determined on In-Room Computerized Tomography (CT) and Electronic Portal Images (EPI). Medical Dosimetry, 2008, 33, 226-233.	0.9	15
63	Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose. International Journal of Radiation Oncology Biology Physics, 2011, 79, 724-731.	0.8	15
64	A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?. Brachytherapy, 2006, 5, 256-261.	0.5	14
65	Radiation for prostate cancer. Lancet Oncology, The, 2001, 2, 73-81.	10.7	13
66	Australasian brachytherapy audit: Results of the â€˜endâ€toâ€endâ€™ dosimetry pilot study. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 490-498.	1.8	13
67	Practical implementation of an existing smoking detection pipeline and reduced support vector machine training corpus requirements. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 27-30.	4.4	12
68	<scp>T</scp>rans <scp>T</scp>asman <scp>R</scp>adiation <scp>O</scp>ncology <scp>G</scp>roup: Development of the <scp>A</scp>ssessment of <scp>N</scp>ew <scp>R</scp>adiation <scp>O</scp>ncology <scp>T</scp>echnology and <scp>T</scp>reatments (<scp>ANROTAT</scp>) <scp>F</scp>ramework. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 363-370.	1.8	12
69	Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants. Brachytherapy, 2005, 4, 146-153.	0.5	11
70	Benchmarking Dosimetric Quality Assessment of Prostate Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 998-1005.	0.8	11
71	A Comparison of In-Room Computerized Tomography Options for Detection of Fiducial Markers in Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1248-1256.	0.8	10
72	Patterns of retreatment with radiotherapy in a large academic centre. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 610-616.	1.8	10

#	Article	IF	Citations
73	Around the Globeâ€“Radiation Oncology in Australia. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1-6.	0.8	9
74	Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology. International Journal of Medical Informatics, 2019, 121, 53-57.	3.3	9
75	Multiparametric 3<scp>T MRI</scp> in the evaluation of intraglandular prostate cancer: Correlation with histopathology. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 439-448.	1.8	8
76	Patterns of health services utilization in the last two weeks of life among cancer patients: Experience in an Australian academic cancer center. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 400-406.	1.1	8
77	Reversible changes in radiation response induced by all-trans retinoic acid. International Journal of Radiation Oncology Biology Physics, 1995, 33, 875-880.	0.8	7
78	Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate International, 2017, 5, 8-12.	2.3	7
79	Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology, 2022, 54, 49-54.	0.6	7
80	Navigating uncertainty: The implementation of Australian radiation therapy advanced practitioners. Technical Innovations and Patient Support in Radiation Oncology, 2021, 17, 82-88.	1.9	6
81	Trends in the use of androgen deprivation in prostate cancer. Acta OncolÃ³gica, 2004, 43, 382-387.	1.8	5
82	Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 739-746.	1.3	5
83	The â€˜Timing of Androgen-Deprivation therapy in incurable prostate cancerâ€™ protocol (TOAD) - where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial. BJU International, 2014, 114, 9-12.	2.5	4
84	Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 549-557.	1.3	4
85	Tribulations of a prostate cancer trial â€“ Lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 508-511.	1.8	3
86	Oncology and nuclear medicine: a developing collaboration. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1229-1231.	2.1	2
87	How Early Is Early: Androgen Deprivation for Prostate-Specific Antigen Relapse in Prostate Cancer. Journal of Clinical Oncology, 2006, 24, 2964-2964.	1.6	2
88	Imaging, radiation oncology and randomised trials: Time for a change?. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 97-100.	1.8	2
89	Researching Depression in Prostate Cancer Patients: Factors, Timing, and Measures. Journal of Men's Health, 2014, 11, 145-156.	0.3	2
90	Testing the <scp>A</scp>ssessment of <scp>N</scp>ew <scp>R</scp>adiation <scp>O</scp>ncology <scp>T</scp>echnology and <scp>T</scp>reatments framework using the evaluation of postâ€prostatectomy radiotherapy techniques. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 129-137.	1.8	2

#	Article	IF	Citations
91	Corrigendum to â€œEfficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Groupâ€•[Radiother Oncol 81 (2006) 9â€“17]. Radiotherapy and Oncology, 2007, 83, 215.	0.6	1
92	Another form of subgroup to beware. Radiotherapy and Oncology, 2011, 101, 525-526.	0.6	1
93	Timing of androgen-deprivation therapy for prostate cancer: still a long way to go â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e313-e314.	10.7	1
94	Trans Tasman Radiation Oncology Group Cancer Research: Phase III â€“ Muscle Invasive Bladder Cancer trial (TROG 02.03): A moral dilemma. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 668-670.	1.8	1
95	Correlation of a bioeffect model with tumor control in localized prostate cancer treated with low-dose-rate brachytherapy. Brachytherapy, 2008, 7, 189.	0.5	0
96	Online Kidney Position Verification Using Non-Contrast Radiographs on a Linear Accelerator with on Board KV X-Ray Imaging Capability. Medical Dosimetry, 2009, 34, 293-300.	0.9	0
97	The Impact of Implant Position Verification Using Gold Fiducials on Urethral Toxicity in Patients with Prostate Cancer Treated with High-Dose-Rate Brachytherapy. Brachytherapy, 2013, 12, S70.	0.5	0
98	In Reply to Jenkins. International Journal of Radiation Oncology Biology Physics, 2015, 91, 243.	0.8	0
99	Timing of androgen-deprivation therapy in prostate cancer â€“ Author's reply. Lancet Oncology, The, 2017, 18, e635.	10.7	0
100	Effective and well tolerated: where do these drugs fit now?. Lancet Oncology, The, 2019, 20, 469-470.	10.7	0
101	Your questions to the PBAC: Prescriptions for flutamide and bicalutamide. Australian Prescriber, 1999, 22, 99.	1.0	0
102	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. JNCI Cancer Spectrum, 0, , .	2.9	0